Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis

References

• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral bg-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367(12):1087-97.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral bg-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107.
   PubMed Web of Science ®Google Scholar
• O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303.
   PubMed Web of Science ®Google Scholar
• Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: A systematic review. Ther Adv Neurol Disord 2012;5(4):205-20.
   PubMedGoogle Scholar
• Smith B, Carson S, Fu R, et al. Drug class review: Disease-modifying drugs for multiple sclerosis. Final Update 1 Report. Portland, Oregon 97239: Oregon Evidence-based Practice Center for the Drug Effectiveness Review Project2010 August 2010.
   Google Scholar
• Weber MS, Menge T, Lehmann-Horn K, et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr Pharm Des 2012;18(2):209-19.
   PubMed Web of Science ®Google Scholar
• Arnoldus JH, Killestein J, Pfennings LE, et al. Quality of life during the first 6 months of interferon-beta treatment in patients with ms. Mult Scler (Houndmills, Basingstoke, England) 2000;6(5):338-42.
   PubMed Web of Science ®Google Scholar
• Simone IL, Ceccarelli A, Tortorella C, et al. Influence of interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 2006;4:96.
   PubMed Web of Science ®Google Scholar
• O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns. Mult Scler 2005;11(1):46-50.
   PubMed Web of Science ®Google Scholar
• Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003;24(5):361-4.
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman A, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the us prospective open-label study of glatiramer acetate. Multiple Sclerosis 2010;16(3):342-50.
   PubMed Web of Science ®Google Scholar
• Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: An overview of merits and culprits. Drug Healthc Patient Saf 2013;5:37-47.
   Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]: The Cochrane Collaboration; 2011. Available at: www.cochrane-handbook.org.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. PLoS Med 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23(20):3105-24.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons, Ltd; 2004. Prior distributions; p. 139-80.
   Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J Clin Epidemiol 2011;64(2):163-71.
   PubMed Web of Science ®Google Scholar
• Lunn DJ, Thomas A, Best N, et al. Winbugs - a bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput 2000;10(4):325-37.
   Web of Science ®Google Scholar
• R development core team. R: A language and environment for statistical computing. R foundation for statistical computing, vienna, austria. 2011. Available at: http://www.R-project.org.
   Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in ms: The evidence trial. Neurology 2002;59(10):1496-506.
   PubMed Web of Science ®Google Scholar
• Oh J, O'Connor PW. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2013;27(8):591-609.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase iii multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology 1995;45(7):1268-76.
   PubMed Web of Science ®Google Scholar
• O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol 2009;8(10):889- 97.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: An extension of the consort statement. Ann Intern Med 2004;141(10):781-8.
   PubMed Web of Science ®Google Scholar
• Boster A, Bartoszek MP, O'Connell C, et al. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2011;4(5):319-32.
   PubMedGoogle Scholar
• Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients. Mult Scler (Houndmills, Basingstoke, England) 2006;12(3):309-20.
   PubMed Web of Science ®Google Scholar
• Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: The north american research committee on multiple sclerosis (narcoms) survey. Health Qual Life Outcomes 2008;6:100.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of bg-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: A systematic review and mixed treatment comparison. Curr Med Res Opin 2013.
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013;73(6):705-13.
   PubMed Web of Science ®Google Scholar